Home » Stocks » TCR2 Therapeutics

TCR2 Therapeutics Inc. (TCRR)

Stock Price: $15.55 USD -0.55 (-3.42%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 374.38M
Revenue (ttm) n/a
Net Income (ttm) -53.20M
Shares Out 24.08M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $15.55
Previous Close $16.10
Change ($) -0.55
Change (%) -3.42%
Day's Open 16.34
Day's Range 15.34 - 16.34
Day's Volume 68,124
52-Week Range 5.84 - 21.06

More Stats

Market Cap 374.38M
Enterprise Value 247.85M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.08M
Float 7.15M
EPS (basic) -2.1
EPS (diluted) -2.21
FCF / Share -2.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 725,679
Short Ratio 4.99
Short % of Float 4.50%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.57
Revenue n/a
Operating Income -56.83M
Net Income -53.20M
Free Cash Flow -51.13M
Net Cash 126.53M
Net Cash / Share 5.26
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.23%
ROE -31.42%
ROIC -44.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(58.65% upside)
Current: 15.55
Target: 24.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-51.38-26.45-13.18-9.92
Net Income-47.60-24.25-13.07-9.92
Shares Outstanding21.100.620.370.28
Earnings Per Share-4.62-98.53-39.94-38.64
Operating Cash Flow-41.36-18.74-12.02-9.38
Capital Expenditures-3.88-1.02-0.39-0.87
Free Cash Flow-45.24-19.76-12.40-10.25
Cash & Equivalents15912320.1016.34
Net Cash / Debt15912320.1016.34
Book Value160-85.70-26.32-11.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name TCR2 Therapeutics Inc.
Country United States
Employees 87
CEO Garry E. Menzel

Stock Information

Ticker Symbol TCRR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TCRR


TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.